



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 33/00, 33/04, 33/14, 33/20, 33/40, A01N 59/00, 59/02, 59/08, A61L 2/00, 2/02, 2/16, 2/18, 9/14, C01B 7/03, 11/00, 13/00, 15/00, C25B 1/00, 1/02, 1/04, 1/14, 1/24, 1/26, 1/28, 1/30, 1/34</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/20287</b>  <b>(43) International Publication Date:</b> 29 April 1999 (29.04.99)
<b>(21) International Application Number:</b> PCT/US98/22372  <b>(22) International Filing Date:</b> 23 October 1998 (23.10.98)  <b>(30) Priority Data:</b> 97/9486                      23 October 1997 (23.10.97)                      ZA  <b>(71) Applicant (for all designated States except US):</b> MOISEL, Ekkehard, Walter [ZA/ZA]; 22 Forge Road, Spartan 1619 (ZA).  <b>(71) Applicant (for BB only):</b> DAVIS, Joanne, T. [US/US]; 714A 15th Street, Arlington, VA 22202 (US).  <b>(71)(72) Applicant and Inventor:</b> HINZE, Gilbert, Theo [ZA/ZA]; 119 Ostrich Road, Bromhof, Randburg 2194 (ZA).  <b>(74) Agent:</b> NATH, Gary, M.; Nath & Associates, 6th floor, 1030 15th Street, N.W., Washington, DC 20005 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> THE USE OF AN AQUEOUS SOLUTION IN THE PREPARATION OF A MEDICAMENT FOR USE IN THE TREATMENT OF LIVE ANIMALS  <b>(57) Abstract</b>  This invention relates to a composition for use in the treatment of pathogenic microorganisms in a live animal, the composition comprising an electro-chemically activated, anion-containing aqueous solution.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

THE USE OF AN AQUEOUS SOLUTION IN THE PREPARATION  
OF A MEDICAMENT FOR USE IN THE TREATMENT OF LIVE  
ANIMALS

Field of the Invention :

This invention relates to the use of an aqueous solution in the preparation of a medicament for use in the treatment of live animals.

Background to the Invention :

For the purposes of this specification, the term "animal" should be construed to include within its meaning sheep, cattle, goats, pigs, chickens, ostriches, reptiles and the like; the term "disease" should be construed to include within its meaning diarrhoea; the term pathogen should be construed to include within its meaning micro-organisms such as E-coli; and the term "medicament" should be construed to include within its meaning oral bactericides and bactericidal inhalants. The Applicant envisages that the invention will be applicable particularly, but not exclusively, in the preparation of a medicament for use in the treatment of pathogenic micro-organisms in weaner piglets and chicklets.

The presence of antibiotic residues in food products lead to allergic and anaphylactic reactions in humans. The development of resistant strains of micro-organisms makes anti-microbials ineffective.

Object of the Invention :

It is accordingly an object of the invention to provide inexpensive, novel and alternative anti-microbials that overcome the above disadvantages.

In accordance with a first aspect of the invention, there is provided the use of a composition in the preparation of a medicament for use in the treatment of pathogenic micro-organisms in a live animal, the composition comprising an electro-chemically activated anion-containing aqueous solution.

5 In accordance with a second aspect of the invention there is provided a composition in the preparation of a medicament for the treatment of pathogenic micro-organisms in live animals, the composition comprising an electro-chemically activated anion-containing aqueous solution, the composition substantially as herein defined.

10 In accordance with a third aspect of the invention there is provided a method of treating pathogenic micro-organisms in a live animal, the method including the step of administering a dosage of a composition comprising an electro-chemically activated anion-containing aqueous solution to the animal, the anion-containing aqueous solution being substantially as herein defined.

15 The anion-containing aqueous solution may be prepared by means of electrolysis of an aqueous solution of a salt. The salt may be sodium chloride. In particular, it may be non-iodated sodium chloride or potassium chloride.

The anion-containing solution and the associated cation-containing solution may be produced by an electro-chemical reactor or so-called electrolysis device.

5 The electro-chemical reactor may include a through flow, electro-chemical cell having two co-axial cylindrical electrodes with a co-axial diaphragm between the electrodes so as to separate an annular inter electrode space into a catalytic and an analytic chamber.

The anion-containing solution is referred to hereinafter for brevity as the "anolyte solution" and the cation-containing solution is referred to hereinafter  
10 for brevity as the "catholyte solution".

The anolyte solution may be produced from an aqueous NaCl solution, electrolysed to produce radical cation and radical anion species, the anolyte solution having a redox potential up to about + 600 mV to + 800 mV. These species may be labile and after about 96 hours, the various radical species may  
15 disappear with no residues being produced.

The anolyte solution may have a pH of about 6,5 to 7,5. The anolyte solution may include species such as  $\text{ClO}$ ;  $\text{ClO}^-$ ;  $\text{HClO}$ ;  $\text{OH}^-$ ;  $\text{HO}_2^-$ ;  $\text{H}_2\text{O}_2$ ;  $\text{O}_3$ ;  $\text{S}_2\text{O}_8^{2-}$  and  $\text{Cl}_2\text{O}_6^{2-}$ .

These species have been found to have a synergistic anti-bacterial and/or anti-viral effect which is generally stronger than that of chemical bactericides and has been found to be particularly effective against viral organisms and spore and cyst forming bacteria.

- 5     The redox potential of the anolyte solution may be monitored during the process so that the treatment process may be monitored and controlled on a continuous basis.

The catholyte solution generally may have a pH of up to about 12-13 and a redox potential of about -980 mV. The catholyte solution may include species  
10     such as NaOH; KOH;  $\text{Ca}(\text{OH})_2$ ;  $\text{Mg}(\text{OH})_2$ ;  $\text{HO}^\cdot$ ;  $\text{H}_3\text{O}_2^\cdot$ ;  $\text{HO}_2^\cdot$ ;  $\text{H}_2\text{O}_2$ ;  $\text{O}_2^\cdot$ ;  $\text{OH}^-$ ;  $\text{O}_2^{2-}$ .

The method of treatment may include administering the anolyte solution by soaking, rinsing or dipping the animal in the anolyte solution, applying the anolyte solution as an inhalant via an atomising or fogging process or  
15     administering the anolyte solution orally. The soaking, rinsing or dipping process is suitable for animals which can be handled with relative ease.

The processes of atomising or fogging and oral administration by addition to drinking water are both suitable for animals such as weaner piglets and

chicklets which are susceptible to stress and accompanying weight loss. The atomising or fogging process may include the step of atomising the solution into the atmosphere in a volume to be treated, forming droplets of between 5 and 100 micrometre. The method may include the preliminary step of enclosing the volume to be treated prior to atomising or fogging the enclosed volume.

The atomising or fogging process is preferably conducted at pre-determined intervals so as to maintain a suitable level of anolyte concentration in the atmosphere, thus utilising the optimum microcidal and other properties of the anolyte solution in accordance with the required administration rate.

The anolyte solution may also be applied by an atomising process in air ducting systems to destroy air-borne micro-organisms and to destroy micro-organisms present in the airways and lung tissue by inhalation.

The treatment of the animal as described above may be conducted so as to improve the weight gain as a result of the anti-microbial action of the anolyte solution.

The oxidising-free radicals present in the anolyte solution may act synergistically at a bacterial cellular level.

The anolyte solution may have a specific anion concentration and distribution and a redox potential in accordance with the specific application.

The pathogenic micro-organisms to be treated may include enteric pathogenic micro-organisms and respiratory pathogenic micro-organisms.

5     Detailed Description of the Invention :

A preferred embodiment of the invention will now be described with reference to the accompanying experiments.

In a series of experiments, the bactericidal effect of the anolyte solution was tested on animals. The results are reflected in the tables below.

10    An electro-chemical reactor, including a through flow, electro-chemical cell having two co-axial cylindrical electrodes with a co-axial diaphragm between them so as to separate an annular inter-electrode space into a catalytic and an analytic chamber, was used to produce anolyte and catholyte solutions.

Experiment 1 - Weaner Piglets

15    The anolyte solution was added to the drinking water of the weaner piglets over a period of 14 days and the results were measured in terms of average

weight after the 14 day period. The average weight of the administered groups were compared with the average weight of the unadministered groups.

The administered groups showed relative weight gain relative to the unadministered groups. The relative weight gains of the administered groups  
5 are reflected in Table 1 below.

### Experiment 2 - Broilers (Chicklets)

Day old broilers were administered with anolyte solution (10% diluted) by addition to drinking water for 7 days. (Group C3 - 12 000 chicklets). No antibiotic medication was administered during that time. Untreated control  
10 groups (C1, C2, C4 and C5 = total 48 000 chicklets) received normal drinking water during that time. The untreated groups were routinely medicated with Tylosin for 3 consecutive days.

Bacterial analyses of the drinking water of all groups were regularly conducted during the first 7 days. Other measurements included daily mortalities and  
15 morbidities throughout and pH and ORP determinations of the drinking water during the first 7 days. All results are reflected in Table 2 below.

Medication of drinking water with anolyte solution supplied to day-old

chicklets for the first period resulted in a significant reduction in mortalities throughout the growth and finishing period. Mortalities increased in all the groups from the 4th week onwards mainly due to respiratory disease. It is envisaged that these could be reduced by fogging the environment with anolyte solution to eliminate airborne respiratory pathogens by means of respiratory intake.

It has been found that the efficacy of the use of the anolyte solution in the treatment of live animals depends upon the concentration of the anions in the anolyte solution, as measured by the oxidation-reduction potential (ORP) or redox potential of the anolyte solution, the flow rate through the reactor, the exposure time, i.e. the contact time between the contaminated animal and the anolyte solution and the temperature during application. By measuring the redox potential of the anolyte solution during the treatment, for example, of a weaner piglet, the available free radical concentration can be monitored. Anolyte solution has been found to be more effective at lower than at higher temperatures.

It will be appreciated that many variations in detail are possible without departing from the scope and/or spirit of the invention as claimed in the claims hereinafter.

1. The use of a composition in the preparation of a medicament for use in the treatment of pathogenic micro-organisms in a live animal, the composition comprising an electro-chemically activated, anion-containing aqueous solution.
2. A composition for the preparation of a medicament for the treatment of pathogenic micro-organisms in live animals, the composition comprising an electro-chemically activated anion-containing aqueous solution.
3. A method of treating pathogenic micro-organisms in a live animal, the method including the step of administering a dosage of a composition comprising an electro-chemically activated anion-containing aqueous solution to the animal
4. A composition as claimed in claim 2 wherein the anion-containing aqueous solution is prepared by means of electrolysis of an aqueous solution of a salt.
5. A composition as claimed in claim 2 wherein the anion-containing solution is produced by an electro-chemical reactor, the electro-chemical

reactor including a through flow, electro-chemical cell having two co-axial cylindrical electrodes with a co-axial diaphragm between the electrodes so as to separate an annular inter electrode space into a catalytic and an analytic chamber.

6. A composition as claimed in claim 2 wherein the anion containing aqueous solution has a redox potential up to about +600 mV and 800 mV and a pH of about 6,5 to 7,5.
7. A method of treatment as claimed in claim 3 including at least one of the steps of administering the solution by soaking, rinsing or dipping the animal in the solution, applying the solution as an inhalant via an atomising or fogging process, and administering the solution orally.
8. A method as claimed in claim 7 wherein the atomising or fogging process includes the step of atomising the solution into the atmosphere in a volume to be treated, forming droplets of between 5 and 100 micrometre..

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/22372

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/600, 613, 615, 616, 661-665, 677-681; 422/22, 23, 29, 37; 252/186.21, 186.22, 187.1-187.32; 205/334, 701, 755, 756.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 5,674,537 A (MORROW) 07 October 1997, column 3, line 28 to column 5, line 19, Example I at column 14, Example IV at column 15, claims 1-6.	1-7 ---- 1-8
X -- Y	US 3,616,355 A (THEMY) 26 October 1971, column 2, lines 16-69, column 3, line 62 to column 4, line 22, column 5, line 15 to column 6, line 36, Example VIII at columns 8-9, claims 1-3.	1-2, 4-6 ----- 1-8
Y	Chem. abstr., Vol. 94, No. 7, 16 November 1981 (Columbus, OH, USA), page 102, column 2, the abstract No. 41943u, SKALIY, P. et al. 'Laboratory Studies of Disinfectants against Legionella pneumophila.' Appl. Environ. Microbiol. 1980, 40(4), 697-700.	1-8

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

19 DECEMBER 1998

Date of mailing of the international search report

21 JAN 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer  
*John Pak*  
JOHN PAK

Telephone No. 308-1235

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/22372

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 33/00, 33/04, 33/14, 33/20, 33/40; A01N 59/00, 59/02, 59/08; A61L 2/00, 2/02, 2/16, 2/18, 9/14; C01B 7/03, 11/00, 13/00, 15/00; C25B 1/00, 1/02, 1/04, 1/14, 1/24, 1/26, 1/28, 1/30, 1/34.

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/600, 613, 615, 616, 661-665, 677-681; 422/22, 23, 29, 37; 252/186.21, 186.22, 187.1-187.32; 205/334, 701, 755, 756.